On Friday, H.C. Wainwright maintained a Buy rating and a $75.00 price target for Silence Therapeutics (NASDAQ:SLN), following the announcement of positive results from their latest clinical trial. Silence Therapeutics reported on Thursday, June 27, 2024, that their Phase 1 SANRECO trial with divesiran (SLN124) showed promising outcomes in treating polycythemia vera (PV), a rare type of blood cancer.
The SANRECO trial evaluated divesiran, a liver-targeted short interfering RNA (siRNA-GalNAc) that focuses on the TMPRSS6 gene. The results indicated a substantial reduction in the need for phlebotomies, a common treatment for PV patients, thanks to sustained reductions in hematocrit (HCT) levels and increased hepcidin levels maintained within physiological norms across all dose groups.
H.C. Wainwright's endorsement of the stock comes as Silence Therapeutics gears up for the next phase in their research. With Phase 1 data aligning with expectations and showcasing divesiran's potential as a leading treatment option, the firm is optimistic about the drug's future. Silence Therapeutics anticipates the commencement of the Phase 2 trial enrollment by the end of 2024.
The maintained price target of $75.00 reflects the firm's confidence in the therapeutic's market potential and its ability to redefine the standard of care for PV patients. The prospect of reducing the need for phlebotomies with divesiran treatment marks a significant step forward in managing this rare blood cancer.
In other recent news, Silence Therapeutics has made significant strides in the biotechnology sector. The company reported positive preliminary results from its SANRECO Phase 1 study of Divesiran, a treatment for polycythemia vera (PV), a rare blood cancer. The drug has been well tolerated and reduced the need for phlebotomy in well-controlled patients. Additionally, Silence Therapeutics announced positive 48-week results from its Phase 2 study of Zerlasiran, a potential treatment for cardiovascular disease.
This study showed a significant reduction in lipoprotein(a) levels, a genetic risk factor for cardiovascular disease. Analyst firms BMO Capital Markets and H.C. Wainwright & Co have maintained positive ratings for Silence Therapeutics, citing the potential of Divesiran and Zerlasiran. In other company news, board member Alistair Gray announced his retirement.
InvestingPro Insights
As Silence Therapeutics (NASDAQ:SLN) advances with its promising divesiran treatment for polycythemia vera, recent data from InvestingPro underscores the financial landscape of the company. With a market capitalization of $853.53 million, the company holds a notable position in the biotech sector. Despite the lack of profitability in the last twelve months, evidenced by a negative P/E ratio of -20.06, analysts remain focused on the company's strong return over the last year, with a staggering 198.74% price total return.
InvestingPro Tips also highlight that Silence Therapeutics holds more cash than debt, providing a solid foundation for future research and development. Additionally, the company's liquid assets exceed its short-term obligations, indicating a healthy financial buffer for upcoming clinical trials. It's worth noting that while analysts do not expect the company to be profitable this year, the high return over the last year and the absence of dividend payments suggest a reinvestment of capital into its core research efforts.
For investors intrigued by the potential of Silence Therapeutics and its place in the biotech industry, more InvestingPro Tips are available, offering deeper insights into the company's financial health and market performance. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription and access to an extended list of tips to guide your investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.